Inclisiran Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 300 mg
Reference Brands: Leqvio (USA/EU)
Category:
Heart Disorder
Inclisiran is a small interfering RNA (siRNA) therapy that works by reducing the production of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in the liver, which in turn increases the number of LDL receptors and helps remove more LDL cholesterol from the blood. It is used to lower LDL cholesterol in patients with high cholesterol (hypercholesterolemia) or atherosclerotic cardiovascular disease, especially when statins alone are insufficient or not tolerated.
Inclisiran is available in injection (prefilled syringe)
and strengths such as 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Inclisiran is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Inclisiran can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing